Posttransplant Lymphoproliferative Diseases

Pediatric Clinics of North America

Volumn 57, Issue 2, 2010, Pages 481-503

  Gross, Thomas G ^a   Savoldo, Barbara ^b   Punnett, Angela ^c  

^a NATIONWIDE CHILDREN S HOSPITAL   (United States)

^b TEXAS CHILDREN S HOSPITAL   (United States)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Pediatric; Posttransplant lymphoproliferative disease; Solid organ transplantation

Indexed keywords

CD21 ANTIBODY; CD23 ANTIBODY; GANCICLOVIR; IMMUNOLOGIC AGENT; RITUXIMAB; UNCLASSIFIED DRUG; VIRUS DNA;

CANCER IMMUNOLOGY; CANCER RISK; CANCER SURVIVAL; CHILD HEALTH; EPSTEIN BARR VIRUS INFECTION; GENE EXPRESSION PROFILING; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEART TRANSPLANTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOPATHOLOGY; HUMAN; IMMUNOPHENOTYPING; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INCIDENCE; INTESTINE TRANSPLANTATION; KIDNEY TRANSPLANTATION; LUNG TRANSPLANTATION; LYMPHADENOPATHY; LYMPHOPROLIFERATIVE DISEASE; MORBIDITY; MORTALITY; ORGAN TRANSPLANTATION; POLYMERASE CHAIN REACTION; POSTOPERATIVE INFECTION; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRIMARY PREVENTION; PROGNOSIS; REVIEW; SCREENING; SECONDARY PREVENTION; SENSITIVITY AND SPECIFICITY; SEROLOGY; SOLID ORGAN TRANSPLANTATION; VIRUS LOAD;

ANTINEOPLASTIC AGENTS; CHILD; EPSTEIN-BARR VIRUS INFECTIONS; HUMANS; IMMUNOSUPPRESSION; IMMUNOTHERAPY; LYMPHOPROLIFERATIVE DISORDERS; ORGAN TRANSPLANTATION; RISK FACTORS; VIRAL LOAD;

EID: 77950963580     PISSN: 00313955     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pcl.2010.01.011     Document Type: Review

References (143)

1. Buell J.F., Gross T.G., Woodle E.S. Malignancy after transplantation. Transplantation 2005, 80(Suppl 2):S254-S264.
2. Bustami R.T., Ojo A.O., Wolfe R.A., et al. Immunosuppression and the risk of post-transplant malignancy among cadaveric first kidney transplant recipients. Am J Transplant 2004, 4(1):87-93.
3. Buell J.F., Gross T.G., Thomas M.J., et al. Malignancy in pediatric transplant recipients. Semin Pediatr Surg 2006, 15(3):179-187.
4. Webber S.A., Naftel D.C., Fricker F.J., et al. Lymphoproliferative disorders after paediatric heart transplantation: a multi-institutional study. Lancet 2006, 367(9506):233-239.
5. Swerdlow S.H., Webber S.A., Chadburn A., et al. Post-transplant lymphoproliferative disorders. WHO classification of tumours of haematopoietic and lymphoid tissues 2008, 343-351. International Agency for Research on Cancer (IARC), Lyon (France). S.H. Swerdlow, E. Campo, N. Lee Harris (Eds.).
6. Chadburn A., Chen J.M., Hsu D.T., et al. The morphologic and molecular genetic categories of posttransplantation lymphoproliferative disorders are clinically relevant. Cancer 1998, 82(10):1978-1987.
7. Chadburn A., Cesarman E., Knowles D.M. Molecular pathology of posttransplantation lymphoproliferative disorders. Semin Diagn Pathol 1997, 14(1):15-26.
8. Djokic M., Le Beau M.M., Swinnen L.J., et al. Post-transplant lymphoproliferative disorder subtypes correlate with different recurring chromosomal abnormalities. Genes Chromosomes Cancer 2006, 45(3):313-318.
9. Maecker B., Jack T., Zimmermann M., et al. CNS or bone marrow involvement as risk factors for poor survival in post-transplantation lymphoproliferative disorders in children after solid organ transplantation. J Clin Oncol 2007, 25(31):4902-4908.
10. Pitman S.D., Huang Q., Zuppan C.W., et al. Hodgkin lymphoma-like posttransplant lymphoproliferative disorder (HL-like PTLD) simulates monomorphic B-cell PTLD both clinically and pathologically. Am J Surg Pathol 2006, 30(4):470-476.
11. Ranganathan S., Webber S., Ahuja S., et al. Hodgkin-like posttransplant lymphoproliferative disorder in children: does it differ from posttransplant Hodgkin lymphoma?. Pediatr Dev Pathol 2004, 7(4):348-360.
12. Rohr J.C., Wagner H.J., Lauten M., et al. Differentiation of EBV-induced post-transplant Hodgkin lymphoma from Hodgkin-like post-transplant lymphoproliferative disease. Pediatr Transplant 2008, 12(4):426-431.
13. Aucejo F., Rofaiel G., Miller C. Who is at risk for post-transplant lymphoproliferative disorders (PTLD) after liver transplantation?. J Hepatol 2006, 44(1):19-23.
14. Leblond V., Davi F., Charlotte F., et al. Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity?. J Clin Oncol 1998, 16(6):2052-2059.
15. Hoshida Y., Li T., Dong Z., et al. Lymphoproliferative disorders in renal transplant patients in Japan. Int J Cancer 2001, 91(6):869-875.
16. Yang F., Li Y., Braylan R., et al. Pediatric T-cell post-transplant lymphoproliferative disorder after solid organ transplantation. Pediatr Blood Cancer 2008, 50(2):415-418.
17. Swerdlow S.H. T-cell and NK-cell posttransplantation lymphoproliferative disorders. Am J Clin Pathol 2007, 127(6):887-895.
18. Afify Z. T-cell post-transplantation lymphoproliferative disorder, a rare and challenging late complication of solid organ transplantation. Pediatr Transplant 2008, 12(6):617-618.
19. Epstein M.A., Achong B.G., Barr Y.M. Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet 1964, 1(7335):702-703.
20. Rickinson A., Kieff E. Epstein-Barr virus. Fields virology 1996, 2397-2446. Lippincott-Raven, Philadelphia. B.N. Fields, D.M. Knipe, P.M. Howley (Eds.).
21. Thorley-Lawson D.A. Epstein-Barr virus: exploiting the immune system. Nat Rev Immunol 2001, 1(1):75-82.
22. Babcock G.J., Hochberg D., Thorley-Lawson A.D. The expression pattern of Epstein-Barr virus latent genes in vivo is dependent upon the differentiation stage of the infected B cell. Immunity 2000, 13(4):497-506.
23. Rickinson A., Kieff E. Epstein-Barr virus. Field's virology 2001, 2575-2627. Lippincott, Williams and Wilkins, Philadelphia. D.M. Knipe, P.M. Howley (Eds.).
24. Hislop A.D., Gudgeon N.H., Callan M.F., et al. EBV-specific CD8+ T cell memory: relationships between epitope specificity, cell phenotype, and immediate effector function. J Immunol 2001, 167(4):2019-2029.
25. Steven N.M., Leese A.M., Annels N.E., et al. Epitope focusing in the primary cytotoxic T cell response to Epstein-Barr virus and its relationship to T cell memory. J Exp Med 1996, 184(5):1801-1813.
26. Amyes E., Hatton C., Montamat-Sicotte D., et al. Characterization of the CD4+ T cell response to Epstein-Barr virus during primary and persistent infection. J Exp Med 2003, 198(6):903-911.
27. Ho M., Jaffe R., Miller G., et al. The frequency of Epstein-Barr virus infection and associated lymphoproliferative syndrome after transplantation and its manifestations in children. Transplantation 1988, 45(4):719-727.
28. Dharnidharka V.R., Sullivan E.K., Stablein D.M., et al. Risk factors for posttransplant lymphoproliferative disorder (PTLD) in pediatric kidney transplantation: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Transplantation 2001, 71(8):1065-1068.
29. Newell K.A., Alonso E.M., Whitington P.F., et al. Posttransplant lymphoproliferative disease in pediatric liver transplantation. Interplay between primary Epstein-Barr virus infection and immunosuppression. Transplantation 1996, 62(3):370-375.
30. McDiarmid S.V., Jordan S., Kim G.S., et al. Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients. Transplantation 1998, 66(12):1604-1611.
31. Dharnidharka V.R., Ho P.L., Stablein D.M., et al. Mycophenolate, tacrolimus and post-transplant lymphoproliferative disorder: a report of the North American Pediatric Renal Transplant Cooperative Study. Pediatr Transplant 2002, 6(5):396-399.
32. Webster A., Woodroffe R.C., Taylor R.S., et al. Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients. Cochrane Database Syst Rev 2005, (4). CD003961.
33. Faull R.J., Hollett P., McDonald S.P. Lymphoproliferative disease after renal transplantation in Australia and New Zealand. Transplantation 2005, 80(2):193-197.
34. Opelz G., Naujokat C., Daniel V., et al. Disassociation between risk of graft loss and risk of non-Hodgkin lymphoma with induction agents in renal transplant recipients. Transplantation 2006, 81(9):1227-1233.
35. Guthery S.L., Heubi J.E., Bucuvalas J.C., et al. Determination of risk factors for Epstein-Barr virus-associated posttransplant lymphoproliferative disorder in pediatric liver transplant recipients using objective case ascertainment. Transplantation 2003, 75(7):987-993.
36. Kauffman H.M., Cherikh W.S., Cheng Y., et al. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 2005, 80(7):883-889.
37. Birkeland S.A., Hamilton-Dutoit S. Is posttransplant lymphoproliferative disorder (PTLD) caused by any specific immunosuppressive drug or by the transplantation per se?. Transplantation 2003, 76(6):984-988.
38. Dharnidharka V.R., Tejani A.H., Ho P.L., et al. Post-transplant lymphoproliferative disorder in the United States: young Caucasian males are at highest risk. Am J Transplant 2002, 2(10):993-998.
39. Opelz G., Dohler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 2004, 4(2):222-230.
40. Petit B., Le Meur Y., Jaccard A., et al. Influence of host-recipient origin on clinical aspects of posttransplantation lymphoproliferative disorders in kidney transplantation. Transplantation 2002, 73(2):265-271.
41. Bond G.J., Mazariegos G.V., Sindhi R., et al. Evolutionary experience with immunosuppression in pediatric intestinal transplantation. J Pediatr Surg 2005, 40(1):274-279. [discussion: 279-80].
42. Gross T.G., Steinbuch M., DeFor T., et al. B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: risk factors, treatment and outcome. Bone Marrow Transplant 1999, 23(3):251-258.
43. Gross T.G. Treatment for Epstein-Barr virus-associated PTLD. Herpes 2009, 15(3):64-67.
44. Bakker N.A., van Imhoff G.W., Verschuuren E.A., et al. Early onset post-transplant lymphoproliferative disease is associated with allograft localization. Clin Transplant 2005, 19(3):327-334.
45. Trpkov K., Marcussen N., Rayner D., et al. Kidney allograft with a lymphocytic infiltrate: acute rejection, posttransplantation lymphoproliferative disorder, neither, or both entities?. Am J Kidney Dis 1997, 30(3):449-454.
46. Nelson B.P., Nalesnik M.A., Bahler D.W., et al. Epstein-Barr virus-negative post-transplant lymphoproliferative disorders: a distinct entity?. Am J Surg Pathol 2000, 24(3):375-385.
47. Verschuuren E., van der Bij W., de Boer W., et al. Quantitative Epstein-Barr virus (EBV) serology in lung transplant recipients with primary EBV infection and/or post-transplant lymphoproliferative disease. J Med Virol 2003, 69(2):258-266.
48. Allen U.D., Farkas G., Hebert D., et al. Risk factors for post-transplant lymphoproliferative disorder in pediatric patients: a case-control study. Pediatr Transplant 2005, 9(4):450-455.
49. Herrmann B.W., Sweet S.C., Molter D.W. Sinonasal posttransplant lymphoproliferative disorder in pediatric lung transplant patients. Otolaryngol Head Neck Surg 2005, 133(1):38-41.
50. Selvaggi G., Sarkar S., Mittal N., et al. Etiology and management of alimentary tract ulcers in pediatric intestinal transplantation patients. Transplant Proc 2006, 38(6):1768-1769.
51. Castellano-Sanchez A.A., Li S., Qian J., et al. Primary central nervous system posttransplant lymphoproliferative disorders. Am J Clin Pathol 2004, 121(2):246-253.
52. Scarsbrook A.F., Warakaulle D.R., Dattani M., et al. Post-transplantation lymphoproliferative disorder: the spectrum of imaging appearances. Clin Radiol 2005, 60(1):47-55.
53. Riebel T., Kebelmann-Betzing C., Scheer I. Ultrasound in abdominal and soft-tissue childhood PTLD (post-transplant lymphoproliferative disease). Ultraschall Med 2007, 28(2):201-205.
54. Bakker N.A., Pruim J., de Graaf W., et al. PTLD visualization by FDG-PET: improved detection of extranodal localizations. Am J Transplant 2006, 6(8):1984-1985.
55. von Falck C., Maecker B., Schirg E., et al. Post transplant lymphoproliferative disease in pediatric solid organ transplant patients: a possible role for [18F]-FDG-PET(/CT) in initial staging and therapy monitoring. Eur J Radiol 2007, 63(3):427-435.
56. Rhodes M.M., Delbeke D., Whitlock J.A., et al. Utility of FDG-PET/CT in follow-up of children treated for Hodgkin and non-Hodgkin lymphoma. J Pediatr Hematol Oncol 2006, 28(5):300-306.
57. McCormack L., Hany T.I., Hubner M., et al. How useful is PET/CT imaging in the management of post-transplant lymphoproliferative disease after liver transplantation?. Am J Transplant 2006, 6(7):1731-1736.
58. Lazda V.A. Evaluation of Epstein-Barr virus (EBV) antibody screening of organ donors for allocation of organs to EBV serostatus matched recipients. Transplant Proc 2006, 38(10):3404-3405.
59. Shroff R., Rees L. The post-transplant lymphoproliferative disorder-a literature review. Pediatr Nephrol 2004, 19(4):369-377.
60. Green M., Michaels M.G., Katz B.Z., et al. CMV-IVIG for prevention of Epstein Barr virus disease and posttransplant lymphoproliferative disease in pediatric liver transplant recipients. Am J Transplant 2006, 6(8):1906-1912.
61. Humar A., Hebert D., Davies H.D., et al. A randomized trial of ganciclovir versus ganciclovir plus immune globulin for prophylaxis against Epstein-Barr virus related posttransplant lymphoproliferative disorder. Transplantation 2006, 81(6):856-861.
62. Opelz G., Daniel V., Naujokat C., et al. Effect of cytomegalovirus prophylaxis with immunoglobulin or with antiviral drugs on post-transplant non-Hodgkin lymphoma: a multicentre retrospective analysis. Lancet Oncol 2007, 8(3):212-218.
63. Funch D.P., Walker A.M., Schneider G., et al. Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients. Am J Transplant 2005, 5(12):2894-2900.
64. Green M., Kaufmann M., Wilson J., et al. Comparison of intravenous ganciclovir followed by oral acyclovir with intravenous ganciclovir alone for prevention of cytomegalovirus and Epstein-Barr virus disease after liver transplantation in children. Clin Infect Dis 1997, 25(6):1344-1349.
65. Green M., Michaels M.G., Webber S.A., et al. The management of Epstein-Barr virus associated post-transplant lymphoproliferative disorders in pediatric solid-organ transplant recipients. Pediatr Transplant 1999, 3(4):271-281.
66. Rowe D.T., Webber S., Schauer E.M., et al. Epstein-Barr virus load monitoring: its role in the prevention and management of post-transplant lymphoproliferative disease. Transpl Infect Dis 2001, 3(2):79-87.
67. Allen U., Hebert D., Petric M., et al. Utility of semiquantitative polymerase chain reaction for Epstein-Barr virus to measure virus load in pediatric organ transplant recipients with and without posttransplant lymphoproliferative disease. Clin Infect Dis 2001, 33(2):145-150.
68. Schubert S., Renner C., Hammer M., et al. Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients. J Heart Lung Transplant 2008, 27(1):100-105.
69. Bingler M.A., Feingold B., Miller S.A., et al. Chronic high Epstein-Barr viral load state and risk for late-onset posttransplant lymphoproliferative disease/lymphoma in children. Am J Transplant 2008, 8(2):442-445.
70. Webber S.A. Post-transplant lymphoproliferative disorders: a preventable complication of solid organ transplantation?. Pediatr Transplant 1999, 3(2):95-99.
71. Kenagy D.N., Schlesinger Y., Weck K., et al. Epstein-Barr virus DNA in peripheral blood leukocytes of patients with posttransplant lymphoproliferative disease. Transplantation 1995, 60(6):547-554.
72. Smets F., Bodeus M., Goubau P., et al. Characteristics of Epstein-Barr virus primary infection in pediatric liver transplant recipients. J Hepatol 2000, 32(1):100-104.
73. Green M., Webber S.A. Persistent increased Epstein-Barr virus loads after solid organ transplantation: truth and consequences?. Liver Transpl 2007, 13(3):321-322.
74. Qu L., Green M., Webber S., et al. Epstein-Barr virus gene expression in the peripheral blood of transplant recipients with persistent circulating virus loads. J Infect Dis 2000, 182(4):1013-1021.
75. Humar A., Michaels M. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant 2006, 6(2):262-274.
76. Stevens S.J., Verschuuren E.A., Pronk I., et al. Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients. Blood 2001, 97(5):1165-1171.
77. Wadowsky R.M., Laus S., Green M., et al. Measurement of Epstein-Barr virus DNA loads in whole blood and plasma by TaqMan PCR and in peripheral blood lymphocytes by competitive PCR. J Clin Microbiol 2003, 41(11):5245-5249.
78. van Esser J.W., Niesters H.G., Thijsen S.F., et al. Molecular quantification of viral load in plasma allows for fast and accurate prediction of response to therapy of Epstein-Barr virus-associated lymphoproliferative disease after allogeneic stem cell transplantation. Br J Haematol 2001, 113(3):814-821.
79. Wagner H.J., Fischer L., Jabs W.J., et al. Longitudinal analysis of Epstein-Barr viral load in plasma and peripheral blood mononuclear cells of transplanted patients by real-time polymerase chain reaction. Transplantation 2002, 74(5):656-664.
80. Bakker N.A., Verschuuren E.A., Veeger N.J., et al. Quantification of Epstein-Barr virus-DNA load in lung transplant recipients: a comparison of plasma versus whole blood. J Heart Lung Transplant 2008, 27(1):7-10.
81. Wagner H.J., Cheng Y.C., Huls M.H., et al. Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood 2004, 103(10):3979-3981.
82. Bakker N.A., Verschuuren E.A., Erasmus M.E., et al. Epstein-Barr virus-DNA load monitoring late after lung transplantation: a surrogate marker of the degree of immunosuppression and a safe guide to reduce immunosuppression. Transplantation 2007, 83(4):433-438.
83. Ahya V.N., Douglas L.P., Andreadis C., et al. Association between elevated whole blood Epstein-Barr virus (EBV)-encoded RNA EBV polymerase chain reaction and reduced incidence of acute lung allograft rejection. J Heart Lung Transplant 2007, 26(8):839-844.
84. Wheless S.A., Gulley M.L., Raab-Traub N., et al. Post-transplantation lymphoproliferative disease: Epstein-Barr virus DNA levels, HLA-A3, and survival. Am J Respir Crit Care Med 2008, 178(10):1060-1065.
85. Henry D.D., Hunger S.P., Braylan R.C., et al. Low viral load post-transplant lymphoproliferative disease localized within the tongue. Transpl Infect Dis 2008, 10(6):426-430.
86. Funk G.A., Gosert R., Hirsch H.H. Viral dynamics in transplant patients: implications for disease. Lancet Infect Dis 2007, 7(7):460-472.
87. Lee T.C., Savoldo B., Barshes N.R., et al. Use of cytokine polymorphisms and Epstein-Barr virus viral load to predict development of post-transplant lymphoproliferative disorder in paediatric liver transplant recipients. Clin Transplant 2006, 20(3):389-393.
88. Baiocchi O.C., Colleoni G.W., Caballero O.L., et al. Epstein-Barr viral load, interleukin-6 and interleukin-10 levels in post-transplant lymphoproliferative disease: a nested case-control study in a renal transplant cohort. Leuk Lymphoma 2005, 46(4):533-539.
89. Lee T.C., Goss J.A., Rooney C.M., et al. Quantification of a low cellular immune response to aid in identification of pediatric liver transplant recipients at high-risk for EBV infection. Clin Transplant 2006, 20(6):689-694.
90. Smets F., Latinne D., Bazin H., et al. Ratio between Epstein-Barr viral load and anti-Epstein-Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease. Transplantation 2002, 73(10):1603-1610.
91. Savoldo B., Rooney C.M., Quiros-Tejeira R.E., et al. Cellular immunity to Epstein-Barr virus in liver transplant recipients treated with rituximab for post-transplant lymphoproliferative disease. Am J Transplant 2005, 5(3):566-572.
92. Green M., Bueno J., Rowe D., et al. Predictive negative value of persistent low Epstein-Barr virus viral load after intestinal transplantation in children. Transplantation 2000, 70(4):593-596.
93. Lee T.C., Savoldo B., Rooney C.M., et al. Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients. Am J Transplant 2005, 5(9):2222-2228.
94. Benden C., Aurora P., Burch M., et al. Monitoring of Epstein-Barr viral load in pediatric heart and lung transplant recipients by real-time polymerase chain reaction. J Heart Lung Transplant 2005, 24(12):2103-2108.
95. Comoli P., Basso S., Zecca M., et al. Preemptive therapy of EBV-related lymphoproliferative disease after pediatric haploidentical stem cell transplantation. Am J Transplant 2007, 7(6):1648-1655.
96. Meerbach A., Wutzler P., Hafer R., et al. Monitoring of Epstein-Barr virus load after hematopoietic stem cell transplantation for early intervention in post-transplant lymphoproliferative disease. J Med Virol 2008, 80(3):441-454.
97. Ghobrial I.M., Habermann T.M., Ristow K.M., et al. Prognostic factors in patients with post-transplant lymphoproliferative disorders (PTLD) in the rituximab era. Leuk Lymphoma 2005, 46(2):191-196.
98. Hayashi R.J., Kraus M.D., Patel A.L., et al. Posttransplant lymphoproliferative disease in children: correlation of histology to clinical behavior. J Pediatr Hematol Oncol 2001, 23(1):14-18.
99. Dror Y., Greenberg M., Taylor G., et al. Lymphoproliferative disorders after organ transplantation in children. Transplantation 1999, 67(7):990-998.
100. Leblond V., Dhedin N., Mamzer Bruneel M.F., et al. Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders. J Clin Oncol 2001, 19(3):772-778.
101. Dotti G., Fiocchi R., Motta T., et al. Lymphomas occurring late after solid-organ transplantation: influence of treatment on the clinical outcome. Transplantation 2002, 74(8):1095-1102.
102. Chadburn A., Cesarman E., Liu Y.F., et al. Molecular genetic analysis demonstrates that multiple posttransplantation lymphoproliferative disorders occurring in one anatomic site in a single patient represent distinct primary lymphoid neoplasms. Cancer 1995, 75(11):2747-2756.
103. Trofe J., Buell J.F., Beebe T.M., et al. Analysis of factors that influence survival with post-transplant lymphoproliferative disorder in renal transplant recipients: the Israel Penn International Transplant Tumor Registry experience. Am J Transplant 2005, 5(4 Pt 1):775-780.
104. Gross T.G., Bucuvalas J.C., Park J.R., et al. Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation. J Clin Oncol 2005, 23(27):6481-6488.
105. Buell J.F., Gross T.G., Hanaway M.J., et al. Posttransplant lymphoproliferative disorder: significance of central nervous system involvement. Transplant Proc 2005, 37(2):954-955.
106. Hanson M.N., Morrison V.A., Peterson B.A., et al. Posttransplant T-cell lymphoproliferative disorders-an aggressive, late complication of solid-organ transplantation. Blood 1996, 88(9):3626-3633.
107. Bierman P.J., Vose J.M., Langnas A.N., et al. Hodgkin's disease following solid organ transplantation. Ann Oncol 1996, 7(3):265-270.
108. Aull M.J., Buell J.F., Trofe J., et al. Experience with 274 cardiac transplant recipients with posttransplant lymphoproliferative disorder: a report from the Israel Penn International Transplant Tumor Registry. Transplantation 2004, 78(11):1676-1682.
109. Choquet S., Oertel S., LeBlond V., et al. Rituximab in the management of post-transplantation lymphoproliferative disorder after solid organ transplantation: proceed with caution. Ann Hematol 2007, 86(8):599-607.
110. Elstrom R.L., Andreadis C., Aqui N.A., et al. Treatment of PTLD with rituximab or chemotherapy. Am J Transplant 2006, 6(3):569-576.
111. Buell J.F., Gross T.G., Hanaway M.J., et al. Chemotherapy for posttransplant lymphoproliferative disorder: the Israel Penn International Transplant Tumor Registry experience. Transplant Proc 2005, 37(2):956-957.
112. Trappe R., Riess H., Babel N., et al. Salvage chemotherapy for refractory and relapsed posttransplant lymphoproliferative disorders (PTLD) after treatment with single-agent rituximab. Transplantation 2007, 83(7):912-918.
113. Windebank K., Walwyn T., Kirk R., et al. Post cardiac transplantation lymphoproliferative disorder presenting as t(8;14) Burkitt leukaemia/lymphoma treated with low intensity chemotherapy and rituximab. Pediatr Blood Cancer 2009, 53(3):392-396.
114. Choquet S., Leblond V., Herbrecht R., et al. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood 2006, 107(8):3053-3057.
115. Oertel S.H., Verschuuren E., Reinke P., et al. Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD). Am J Transplant 2005, 5(12):2901-2906.
116. Perrine S.P., Hermine O., Small T., et al. A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. Blood 2007, 109(6):2571-2578.
117. Benkerrou M., Jais J.P., Leblond V., et al. Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: prognostic factors and long-term outcome. Blood 1998, 92(9):3137-3147.
118. Pescovitz M.D. Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action. Am J Transplant 2006, 6(5 Pt 1):859-866.
119. Choquet S., Trappe R., Leblond V., et al. CHOP-21 for the treatment of post-transplant lymphoproliferative disorders (PTLD) following solid organ transplantation. Haematologica 2007, 92(2):273-274.
120. Machado A.S., Apa A.G., Magalhaes de Rezende L.M., et al. Plasma Epstein-Barr viral load predicting response after chemotherapy for post-transplant lymphoproliferative disease. Clin Exp Med 2008, 8(2):129-132.
121. Yang J., Tao Q., Flinn I.W., et al. Characterization of Epstein-Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: disappearance after rituximab therapy does not predict clinical response. Blood 2000, 96(13):4055-4063.
122. Papadopoulos E.B., Ladanyi M., Emanuel D., et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 1994, 330(17):1185-1191.
123. Heslop H.E., Brenner M.K., Rooney C.M. Donor T cells to treat EBV-associated lymphoma. N Engl J Med 1994, 331(10):679-680.
124. Savoldo B., Goss J.A., Hammer M.M., et al. Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs). Blood 2006, 108(9):2942-2949.
125. Rooney C.M., Smith C.A., Ng C.Y., et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 1998, 92(5):1549-1555.
126. Haque T., Amlot P.L., Helling N., et al. Reconstitution of EBV-specific T cell immunity in solid organ transplant recipients. J Immunol 1998, 160(12):6204-6209.
127. Sherritt M.A., Bharadwaj M., Burrows J.M., et al. Reconstitution of the latent T-lymphocyte response to Epstein-Barr virus is coincident with long-term recovery from posttransplant lymphoma after adoptive immunotherapy. Transplantation 2003, 75(9):1556-1560.
128. Gerdemann U., Christin A.S., Vera J.F., et al. Nucleofection of DCs to generate Multivirus-specific T cells for prevention or treatment of viral infections in the immunocompromised host. Mol Ther 2009, 17(9):1616-1625.
129. Vera JF, Brenner LJ, Gerdemann U, et al. Accelerated production of antigen-specific T-cells for pre-clinical and clinical applications using Gas-permeable Rapid Expansion cultureware (G-Rex). Mol Ther 2010, in press.
130. Savoldo B., Cubbage M.L., Durett A.G., et al. Generation of EBV-specific CD4+ cytotoxic T cells from virus naive individuals. J Immunol 2002, 168(2):909-918.
131. Comoli P., Ginevri F., Maccario R., et al. Successful in vitro priming of EBV-specific CD8+ T cells endowed with strong cytotoxic function from T cells of EBV-seronegative children. Am J Transplant 2006, 6(9):2169-2176.
132. Sun Q., Burton R., Reddy V., et al. Safety of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for patients with refractory EBV-related lymphoma. Br J Haematol 2002, 118(3):799-808.
133. Haque T., Taylor C., Wilkie G.M., et al. Complete regression of posttransplant lymphoproliferative disease using partially HLA-matched Epstein Barr virus-specific cytotoxic T cells. Transplantation 2001, 72(8):1399-1402.
134. Gandhi M.K., Wilkie G.M., Dua U., et al. Immunity, homing and efficacy of allogeneic adoptive immunotherapy for posttransplant lymphoproliferative disorders. Am J Transplant 2007, 7(5):1293-1299.
135. Haque T., Wilkie G.M., Jones M.M., et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood 2007, 110(4):1123-1131.
136. Quintarelli C., Vera J.F., Savoldo B., et al. Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes. Blood 2007, 110(8):2793-2802.
137. Dotti G., Savoldo B., Pule M., et al. Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis. Blood 2005, 105(12):4677-4684.
138. De Angelis B., Dotti G., Quintarelli C., et al. Generation of Epstein-Barr-virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506). Blood 2009, 114(23):4784-4791.
139. Brewin J., Mancao C., Straathof K., et al. Generation of EBV-specific cytotoxic T-cells that are resistant to calcineurin inhibitors for the treatment of posttransplantation lymphoproliferative disease. Blood 2009, 114(23):4792-4803.
140. Dharnidharka V.R., Araya C.E. Post-transplant lymphoproliferative disease. Pediatr Nephrol 2009, 24(4):731-736.
141. Koch D.G., Christiansen L., Lazarchick J., et al. Posttransplantation lymphoproliferative disorder-the great mimic in liver transplantation: appraisal of the clinicopathologic spectrum and the role of Epstein-Barr virus. Liver Transpl 2007, 13(6):904-912.
142. International Transplant Registry Pediatric data Available at:, Accessed October 30, 2009. http://www.intestinaltransplantregistry.org.
143. Allen U., Hebert D., Moore D., et al. Epstein-Barr virus-related post-transplant lymphoproliferative disease in solid organ transplant recipients, 1988-97: a Canadian multi-centre experience. Pediatr Transplant 2001, 5(3):198-203.